{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:02:30Z","timestamp":1783612950729,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jtho.2023.04.020","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T01:11:54Z","timestamp":1683162714000},"page":"1094-1102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1\u2013Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Edward B.","family":"Garon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Papadimitrakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Antonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Powderly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette J.","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairouz","family":"Elgeioushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.04.020_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.020_bib2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2023.04.020_bib3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.020_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.817548","article-title":"The landscape of immunotherapy resistance in NSCLC","volume":"12","author":"Frisone","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib5","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2023.04.020_bib6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.020_bib7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jamaoncol.2021.2209","article-title":"Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the Lung-MAP S1400I phase 3 randomized clinical trial","volume":"7","author":"Gettinger","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib8","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2023.04.020_bib9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.020_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer ATLANTIC: an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib11","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","article-title":"Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC","volume":"14","author":"Antonia","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2023.04.020_bib12","article-title":"Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial","volume":"39","author":"Spigel","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib14","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2023.04.020_bib15","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.jtho.2021.08.029","article-title":"PL02.01 Durvalumab \u00b1 tremelimumab\u00a0+ chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study","volume":"16","author":"Johnson","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib16","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/JTO.0000000000000693","volume":"10","author":"Paz-Ares","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.immuni.2016.12.004","article-title":"Too much of a good thing? Chronic IFN fuels resistance to cancer immunotherapy","volume":"45","author":"Reading","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2023.04.020_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","article-title":"Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy","volume":"27","author":"Ferrara","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.04.020_bib19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T\u00a0cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jtho.2023.04.020_bib20","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2023.04.020_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2023.04.020_bib22","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1158\/1078-0432.CCR-18-3740","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers\u2014letter","volume":"25","author":"Ferrara","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.04.020_bib23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib24","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2023.04.020_bib25","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","article-title":"Deciphering radiological stable disease to immune checkpoint inhibitors","volume":"33","author":"Luo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.04.020_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/PO.20.00021","article-title":"Comparison of fast-progression, hyperprogressive disease, and early deaths in advanced non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors or chemotherapy","volume":"4","author":"Ferrara","year":"2020","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423005245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423005245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:57:00Z","timestamp":1719968220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423005245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1556086423005245"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.04.020","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1\u2013Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}